Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular-related ...

These results demonstrate that we can capture thousands of atheroembolic particles during renal stenting procedures under protection, and that increasing captured particle counts greater than 60 ...

A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for kidney failure. The U.S. Food and Drug Administration (FDA) has ...